Lilly submits Cymbalta NDA for generalized anxiety disorder
Key points
- Eli Lilly and Company has announced the recent submission of a supplemental New Drug Application (sNDA) to the U.S.
- Cymbalta is already approved in the United States for the treatment of major depressive disorder and the management of diabetic peripheral neuropathic pain, both in adults.
- "More than three million patients worldwide have been treated with Cymbalta since its approval from the FDA for the treatment of major depression and management of diabetic nerve pain," said Alan Breier, M.D., vice president - medical and chief medical officer, Eli Lilly and Company.
- Every year four million Americans age 18 to 54 are diagnosed with generalized anxiety disorder, the majority of them women.
Eli Lilly and Company has announced the recent submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Cymbalta (duloxetine HCl) for the treatment of generalized anxiety disorder.
Cymbalta is already approved in the United States for the treatment of major depressive disorder and the management of diabetic peripheral neuropathic pain, both in adults. Lilly is also conducting Phase III studies on Cymbalta and its effects on fibromyalgia, a chronic, often debilitating pain disorder characterized by widespread muscle aches, pain and stiffness in muscles, and often accompanied by fatigue and sleep disturbance.
"More than three million patients worldwide have been treated with Cymbalta since its approval from the FDA for the treatment of major depression and management of diabetic nerve pain," said Alan Breier, M.D., vice president - medical and chief medical officer, Eli Lilly and Company. "Lilly is committed to fully exploring other unmet patient needs, and looks forward to conducting further research with this innovative drug."
Every year four million Americans age 18 to 54 are diagnosed with generalized anxiety disorder, the majority of them women. It is common for people with generalized anxiety disorder to also experience other physical and mental disorders, including depression, eating disorders or substance abuse.(iii) Because generalized anxiety disorder presents with a variety of symptoms, both anxious and physical, it can be difficult to diagnose.(iv) When left untreated, symptoms may get progressively worse, significantly diminishing a patient's quality of life.
http://www.lilly.com
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Mental Health →
NewsNeuroscientists determine how treatment for anxiety disorders silences fear neurons
Excessive fear can develop after a traumatic experience, leading to anxiety disorders such as post-traumatic stress disorder and phobias. During exposure therapy, an effective and common treatment for anxiety disorders,…
2 November 2013
NewsFake Xanax anxiety pills from China seized in Zurich
Customs agents have seized one million fake anti-anxiety pills in transit at Zurich airport, Swiss officials say. The four-crate shipment was on its way from China to Egypt, the Swiss Agency for Therapeutic Products…
21 October 2013
NewsBoston University Researchers Test Effectiveness of Behavioral and Medication Treatments for Patients with Alcoholism and Anxiety
Domenic Ciraulo, MD, chair of psychiatry at Boston University School of Medicine (BUSM) and David H. Barlow, PhD, professor of psychology at Boston University (BU), have collaborated to study the effect of behavioral…
